Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TriSalus Life SciencesTLSI +0.57%26 Piotroski F-Score is 5 as of Aug. 23, 2026, which is 25% above its 10-year median of 4.00. GuruFocus rates TLSI with a GF Score™ of 26/100 and a GF Value™ of $3.77 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 808 Medical Devices & Instruments companies, TriSalus Life Sciences ranks better than 63% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
TriSalus Life Sciences has an F-score of 5 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for TriSalus Life Sciences's Piotroski F-Score or its related term are showing as below:
TLSI'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 4 Max: 5
Current: 5
During the past 5 years, the highest Piotroski F-Score of TriSalus Life Sciences was 5. The lowest was 3. And the median was 4.
TriSalus Life Sciences (NAS:TLSI) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
TriSalus Life Sciences Piotroski F-Score Related Terms
TriSalus Life Sciences Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for TriSalus Life Sciences's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TLSI vs TMCI, SENS, SGHT: Piotroski F-Score Comparison
For the Medical Devices subindustry, TriSalus Life Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
TriSalus Life Sciences's current Net Income (TTM) was -28.21.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
TriSalus Life Sciences's current Cash Flow from Operations (TTM) was -22.80.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
TriSalus Life Sciences's return on assets of this year was -0.68281821. TriSalus Life Sciences's return on assets of last year was -0.96111745.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
TriSalus Life Sciences's gearing of this year was 0.69323999. TriSalus Life Sciences's gearing of last year was 1.09019575.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
TriSalus Life Sciences's current ratio of this year was 5.34765485. TriSalus Life Sciences's current ratio of last year was 4.08451308.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
TriSalus Life Sciences's number of shares in issue this year was 58.297. TriSalus Life Sciences's number of shares in issue last year was 32.899.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
TriSalus Life Sciences's gross margin of this year was 0.85788761. TriSalus Life Sciences's gross margin of last year was 0.84670742.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
TriSalus Life Sciences's asset turnover of this year was 1.0910037. TriSalus Life Sciences's asset turnover of last year was 1.10974068.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
1
+
1
+
1
+
0
+
1
+
0
=
5
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
TriSalus Life Sciences has an F-score of 5 indicating the company's financial situation is typical for a stable company.
TriSalus Life Sciences (TLSI) has a Piotroski F-Score of 5 as of Aug. 23, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on TriSalus Life Sciences and its competitors. This is 25% above median its historical median of 4.00. Over the past decade, TriSalus Life Sciences' Piotroski F-Score has ranged from 3.00 to 5.00. According to the industry distribution chart, TriSalus Life Sciences ranks #299 out of 808 companies in the Medical Devices & Instruments industry, placing it in the top 37%.
Is TriSalus Life Sciences' Piotroski F-Score too high?
TriSalus Life Sciences' current Piotroski F-Score of 5 is 25% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 5.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. TriSalus Life Sciences' value of 5 is 0% at this industry median. Based on the distribution chart, TriSalus Life Sciences ranks #299 out of 808 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, TriSalus Life Sciences has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Piotroski F-Score compare to TMCI and SENS?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #299 out of 808 companies for Piotroski F-Score. This puts TriSalus Life Sciences in the upper half of its industry. The industry median Piotroski F-Score is 5.00. TriSalus Life Sciences' value of 5 is 0% at this benchmark. Historically, TriSalus Life Sciences' own Piotroski F-Score has ranged from 3.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, TriSalus Life Sciences has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TriSalus Life Sciences's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on TriSalus Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current Piotroski F-Score is 5, which is 25% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.77, compared to a current price of $5.27 — trading 39.8% above its estimated fair value. The current Piotroski F-Score is 5, which is 25% above median its 10-year median of 4.00 and 0% at the Medical Devices & Instruments industry median of 5.00. TriSalus Life Sciences' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Piotroski F-Score is 5 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be overvalued.
The current stock price of $5.27 is trading 39.8% above its estimated GF Value™ of $3.77.
GuruFocus considers TriSalus Life Sciences to be Significantly Overvalued.
Key valuation signals for TLSI:
Piotroski F-Score: 5 (25% above median its 10-year median of 4.00)
GF Value™: $3.77 vs. price of $5.27 (39.8% above fair value)
Industry Position: 0% at the Medical Devices & Instruments median (#299 of 808)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
26GF Score
Get the complete analysis for TLSI
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
